BMS Inks US$3.63 B Immuno-Oncology Collaboration with Nektar Therapeutics
By Arun Manohar
Pharma Deals Review: Vol 2018 Issue 2 (Table of Contents)
Published: 27 Feb-2018
DOI: 10.3833/pdr.v2018.i2.2306 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Augmenting its immuno-oncology pipeline, Bristol-Myers Squibb (BMS) has announced a global development and commercialisation collaboration with Nektar Therapeutics that is potentially worth up to US$3...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS